TyRx surgical mesh
This article was originally published in Clinica
Executive Summary
TyRx Pharma has received US FDA 510(k) clearance for its bioresorbable polymer-coated surgical mesh for repairing hernias and other abdominal fascial or muscular deficiencies that require a reinforcing material to improve surgical results. The product incorporates features that the firm believes will help alleviate some of the problems associated with the use of synthetic mesh implants. It has handling characteristics that facilitate its precise placement during a surgical repair and leave less implant material following the resorption of the bioresorbable polymer coating. Less implant material should help facilitate patient comfort during the post-operative period and beyond, said the Monmouth, Junction, New Jersey firm. The mesh is scheduled for launch in the first quarter of this year.